• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Manufacturing
    • Packaging
    • Development
    • Compliance
    • Top 25
    • Directory
    • Microsites
    • Events
    • More
  • Magazine
  • News
  • Manufacturing
  • Packaging
  • Development
  • Compliance
  • Top 25
  • Directory
  • Microsites
  • Events
  • Current / Back Issue
    Features
    Editorial
    Columns
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Subscribe Now
    Advertise Now
    Top Features
    Bye-Bye China?

    Decentralized Trials Fuel AI Revolution in Clinical Research

    Self-Medication: Flexibility for Patients and Drug Manufacturers

    The Single-Use Mixing Landscape: Evaluating Your Options

    DCAT President Talks COVID-19, Drug Manufacturing and Innovation
    Breaking News
    Online Exclusives
    Industry News
    Collaborations & Alliances
    Promotions & Moves
    Trials & Filings
    Financial Reports
    Bio News & Views
    Custom Sourcing News
    Packaging & Tracking
    CRO News
    Live From Shows
    Top News
    Global Biosciences Co. Selects ValGenesis VLMS

    Eisai Appoints Chief Clinical Officer of Oncology Biz

    Nexelis Acquires GSK Vax Lab in Marburg

    Bone Therapeutics, Rigenerand Ink Cell Therapy Deal

    NovaQuest Private Equity Acquires CoreRx
    APIs
    Aseptic Processing
    Cleaning Validation
    Clinical Trial Materials
    Cytotoxics and High Potency Manufacturing
    Equipment
    Excipients
    Extractables and Leachables
    Facilities
    Fill/Finish
    Lyophilization
    Parenterals
    Process Development
    Process Validation
    Risk Management
    Scale-up/ Technology Transfer
    Solid Dosage/ Creams/ Ointments

    Lonza to Exit Pharma Softgels and Liquid-Filled Hard Capsules

    Cognate BioServices Announces Major Expansion

    Sanofi Unveils EUROAPI as Name of New European API Company

    Precision Medicine Group Acquires Project Farma

    Cytiva Delivers Modular Biologics Factory to Lonza
    Capsules
    Cold Chain Management
    Injectables
    Logistics
    Serialization
    Solid Dosage / Semi-solids
    Supply Chain
    Vials

    Catalent Acquires Acorda’s INBRIJA Manufacturing Operations

    Varcode, PL Developments Form Strategic ‘Smart Tag’ Pact

    COVID-19 Vaccine Distribution: The Air Cargo Industry’s Greatest Challenge

    Thermo Fisher Expands Clinical Supply Services in Europe

    Schreiner MediPharm Joins DoseID Consortium
    Analytical Services
    Bioanalytical Services
    Bioassay Developement
    Biologics, Proteins, Vaccines
    Biosimilars
    Chemistry
    Clinical Trials
    Drug Delivery
    Drug Development
    Drug Discovery
    Formulation Development
    Information Technology
    Laboratory Testing
    Methods Development
    Microbiology
    Preclinical Outsourcing
    R&D
    Toxicology

    Global Biosciences Co. Selects ValGenesis VLMS

    Nexelis Acquires GSK Vax Lab in Marburg

    The Future of Clinical Trials Series: Part I

    JS Bio and Etta Biotech Advancing Partnership

    Intravacc Completes Project for Provention Bio’s Vax Candidate
    Filtration & Purification
    GMPs/GCPs
    Inspections
    QA/QC
    Regulatory Affairs
    Validation

    Global Biosciences Co. Selects ValGenesis VLMS

    Gene Therapy Co. Selects ValGenesis' SaaS Platform

    The Year of COVID: How FDA Coped with a Worldwide Pandemic in 2020 and What to Expect in 2021

    Samsung Biologics Adopts Veeva Vault QMS to Unify Quality Management

    CDMO Cognate BioServices Teams Up with L7 Informatics
    Companies
    Categories
    Corporate Capabilities
    Add New Company
    Contract Service Directory Companies
    Emergent BioSolutions

    Adare Pharma Solutions

    Reed-Lane

    Syngene

    Baxter BioPharma Solutions
    Companies
    News Releases
    Posters
    Brochures
    Services
    Videos
    Case Study
    White Papers
    Jobs
    Contract Service Directory Companies
    Emergent BioSolutions

    Baxter BioPharma Solutions

    Flow Sciences

    Adare Pharma Solutions

    Reed-Lane
    Webinars
    Live From Shows
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
      • Enewsletter Archive
      • Digital Edition
    • Directory
      • Companies
      • Categories
      • Corporate Capabilities
      • Add Your Company
    • Manufacturing
      • APIs
      • Aseptic Processing
      • Cleaning Validation
      • Clinical Trial Materials
      • Cytotoxics and High Potency Manufacturing
      • Equipment
      • Excipients
      • Extractables and Leachables
      • Facilities
      • Fill/Finish
      • Lyophilization
      • Parenterals
      • Process Development
      • Process Validation
      • Risk Management
      • Scale-up/ Technology Transfer
      • Solid Dosage/ Creams/ Ointments
      • cGMP Manufacture
    • Packaging
      • Capsules
      • Cold Chain Management
      • Injectables
      • Logistics
      • Serialization
      • Solid Dosage / Semi-solids
      • Supply Chain
      • Vials
    • Development
      • Analytical Services
      • Bioanalytical Services
      • Bioassay Developement
      • Biologics, Proteins, Vaccines
      • Biosimilars
      • Chemistry
      • Clinical Trials
      • Drug Delivery
      • Drug Development
      • Drug Discovery
      • Formulation Development
      • Information Technology
      • Laboratory Testing
      • Methods Development
      • Microbiology
      • Preclinical Outsourcing
      • R&D
      • Toxicology
    • Compliance
      • Filtration & Purification
      • GMPs/GCPs
      • Inspections
      • QA/QC
      • Regulatory Affairs
      • Validation
    • Top 25 Pharma & BioPharma
    • Contract Pharma Direct
    • Breaking News
    • Online Exclusives
    • Slideshows
    • Experts Opinions
    • Surveys
      • Outsourcing Survey
      • Salary Survey
    • Glossary
    • Videos
    • Podcasts
    • White Papers
    • Infographics
    • Contract Pharma Conference
      • Contract Pharma Conference
      • Speakers
      • Exhibitors
      • Conference Sessions
    • Supplier Microsite
      • Companies
      • News Releases
      • Posters
      • Brochures
      • Services
      • Videos
      • Case Study
      • White Papers
    • eBook
    • Webinars
    • Events
      • Industry Events
      • Live from Show Events
      • Webinars
    • Classifieds / Job Bank
      • Classifieds
      • Job Bank
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    Features

    Manufacturing of Solid Dosage Forms

    Why outsourcing may represent the most viable pathway for innovators

    Manufacturing of Solid Dosage Forms
    Erik Haeffler, VP of Manufacturing Services and Head of Sustainability, Recipharm05.05.20
    The trend towards outsourcing solid dose manufacturing has been driven by the ever more complex nature of new molecules. Innovators are choosing to share the burden of challenges relating to bioavailability, formulation, stability, manufacturability and, not to mention, scalability. Industry pressures to reduce development times and costs, as well as increasing numbers of smaller drug developers now taking molecules to market independently, are spurring partnerships with contract development and manufacturing organizations (CDMOs) who can bring formulation expertise, global experience and broad service offerings. This article looks at the growing market for oral solid dose (OSD) development, addressing the operational challenges faced. It will also shed light on how outsourcing may be key in bringing increased flexibility and capacity to the manufacture of these drug forms.

    The solid dosage landscape
    It was expected among industry peers that OSD manufacturing activity would decline when, in fact, the opposite has been true. There are many reasons why OSD forms remain the most popular, including their relative ease of manufacture, cost-effectiveness and patient-friendly nature. They also offer significant benefits to manufacturers such as trouble-free packaging and transportation, as well as increased chemical and physical stability.1 In addition, they present an opportunity to extend product lifecycles. Advances in drug delivery are now enabling OSDs to achieve better bioavailability through the adoption of novel drug delivery technologies, such as extended, controlled and rapid release systems. From the patient perspective, these can offer inherent advantages in dose administration and can be formulated in varying dosage forms to increase patient compliance.

    Future Market Insights (FMI) forecasts the global OSD pharmaceutical formulation market to grow from $493 billion in 2017 to $926 billion by the end of 2027. This represents a value compound annual growth rate (CAGR) of 6.5% over the forecast period.1

    As demand has shifted from a ‘blockbuster’ paradigm to more complex active pharmaceutical ingredients (APIs) and smaller batches, OSD development and manufacturing poses operational challenges for pharmaceutical firms. Today, many changes are occurring in OSD manufacturing with different chemistries being used that require new approaches and the implementation of continuous processing. Demand is therefore high for CDMOs that can bring both formulation expertise in this area, as well as flexible manufacturing capacity.

    Solid dose projects
    Today, the industry is seeing evidence that three types of manufacturing projects are driving the OSD outsourcing market. First, there are customers with high volume products that are looking for an improved set-up from a total cost of supply point of view. While previously customers would typically consider just the cost of contract manufacturing, they are increasingly recognizing that there are other factors at play. For example, the location of manufacturing can cause issues, slowing down the supply chain and, in some cases, jeopardize supply.

    With more products requiring complex manufacturing processes, developers are also struggling to find the required technical set-up which is also manageable from a cost standpoint. Consequently, they are recognizing that CDMOs that can offer a breadth of capabilities may be better positioned to help them simplify their supply chain during OSD manufacturing projects.

    Finally, it is becoming more and more common that relatively small/virtual companies are developing new drugs that they do not intend to manufacture themselves. In this case, they are choosing to partner with CDMOs with development capabilities from the start.

    Outsourcing advantages
    Outsourcing not only serves to streamline development processes, while offering more flexible manufacturing, but it can bring wider access to expertise, helping to mitigate risk for developers. It also reduces the need for in-house resources and allows a developer’s team to focus on core R&D competencies.

    Despite OSD drugs being one of the oldest, most popular forms, their development and manufacture still presents many challenges and opportunities. The need for specialized processing technologies to enable controlled release products, satisfy containment needs and produce combination products with several APIs, is one of the main drivers for increased outsourcing. Responsive and flexible CDMOs that possess the ability to address the challenges and leverage the opportunities can help alleviate much of the perceived burden for developers.

    In selecting a CDMO, customers should look for a clean compliance record, good supply service and a strong reputation for on-time delivery, as well as value for money through an attractive total cost of supply. Increasingly, developers expect that a CDMO will take responsibility for project management. Consequently, being able to forge a strong, strategic relationship and build solid communication with a partner is becoming a more fundamental part of the outsourcing partnership; improving efficiencies and reducing costs cannot be achieved without dialogue and understanding between developer and supplier. Therefore, close attention should be paid to how a CDMO intends to set-up a pragmatic communication network between themselves and the developer.

    It is also critical to consider early on if a CDMO’s capabilities are compatible with a developer’s later stage requirements. This will be fundamental to achieving a seamless transition through the development phases into commercialization. Many developers prefer to work with CDMOs that can scale formulations from the laboratory to GMP clinical and ultimately commercial manufacturing. CDMOs that offer these capabilities can help to eliminate the risk, time and cost associated with technology transfer and the need to manage multiple suppliers. The robustness of manufacturing processes, capacity, trouble-shooting expertise and access to global resources are also key attributes that should be considered a priority for developers.

    Another key driver should be the CDMO’s capability to meet shorter timelines while maintaining a high level of quality. Therefore, developers should look to gain a good understanding of the internal systems, processes and procedures that a CDMO has in place to be as efficient as possible in ensuring a project meets its milestones.

    Developers should also seek to work with CDMOs that can offer a comprehensive understanding of their drug substance. A partner should understand how the substance behaves during processing, including its solubility in solvents and buffer systems, compatibility with excipients, stability under various physiological conditions, solid-state characteristics and physiochemical properties. These details will be essential in the selection of the right delivery system and the development of an optimal drug formulation. This point is particularly crucial in today’s industry where many challenging and complex compounds are subject to poor solubility. Finding the correct formulation solutions which are faster to scale-up and less likely to fail at a later stage of development is critical in a product reaching the point of commercial manufacture. 

    In dealing with complex projects there will always be technical challenges. High volume projects also bring their own unique set of obstacles. Identifying a CDMO that can demonstrate expertise in navigating difficult manufacturing projects and can readily identify where any problematic areas are likely to exist is paramount to success.

    Conclusion
    While OSD products may seem outdated compared with the steep increase in new biopharmaceutical products, they nevertheless will continue to constitute a major share of all medicines for the foreseeable future. At a time when more complex molecules are calling for more diverse technical requirements and supply chain needs, the outsourcing relationship has never been more important. 

    CDMOs that can offer developers expertise in formulation development and can achieve seamless scale-up and technology transfer for commercial manufacturing offer a clear advantage in supporting the manufacture of complex OSDs. 

    References
    1. https://www.futuremarketinsights.com/reports/oral-solid-dosage-pharmaceutical-formulation-market


    Erik Haeffler is the vice president of manufacturing services and the head of sustainability at Recipharm. He is responsible for the group’s sustainability work, as well as its focus on operational and commercial excellence. As part of his role, Erik is continuously developing a model for working with multi-site projects and is accountable for operations development across the company, including elements such as project management resources, corporate IS and project/product sourcing decisions.

    Related Features

    • Excipients
      Bye-Bye China?

      Bye-Bye China?

      Instead of closing its doors on China, Western pharma industry needs to take a balanced approach and perform proper due diligence based on objective criteria.
      Michele Jermini and Enrico Polastro 11.17.20

    • Clinical Trials | Information Technology | R&D
      Decentralized Trials Fuel AI Revolution in Clinical Research

      Decentralized Trials Fuel AI Revolution in Clinical Research

      The life sciences industry is giving clinical a full makeover, dramatically improving how new therapeutics are developed.
      Nick Moss, Vice President of Analytics and Machine Learning, Medable 11.17.20

    • Drug Delivery | Injectables
      Self-Medication: Flexibility for Patients and Drug Manufacturers

      Self-Medication: Flexibility for Patients and Drug Manufacturers

      Bringing together self-medication with auto-injectors and sustainable secondary packaging.
      Matthias Heinrichs, Head of Product Management and Project Engineering, Syntegon Technology 11.17.20


    • The Single-Use Mixing Landscape: Evaluating Your Options

      The Single-Use Mixing Landscape: Evaluating Your Options

      Adoption of single-use technologies has increased markedly in recent years and will continue to grow.
      Mark A. Sitcoske, Founder & CEO, High Purity New England 11.17.20

    • DCAT President Talks COVID-19, Drug Manufacturing and Innovation

      DCAT President Talks COVID-19, Drug Manufacturing and Innovation

      Lonza’s Director of Commercial Development, Sean Diver, was recently named President of DCAT.
      Tim Wright, Editor, Contract Pharma 11.17.20

    • Biologics, Proteins, Vaccines | Biosimilars | Drug Development
      Biopharma Contract Manufacturing: Robust Growth Ahead

      Biopharma Contract Manufacturing: Robust Growth Ahead

      The biopharmaceutical contract manufacturing market is projected to reach $6.3 billion in 2020, and it will continue to grow over the next five years.
      William Downey, HighTech Business Decisions 11.17.20


    • Injectables
      Catering for the Complex

      Catering for the Complex

      The rapidly changing landscape of pharmaceutical packaging.
      Marcelo Cruz, Director Business Development and Marketing, Tjoapack 11.17.20

    • Cold Chain Management | Supply Chain
      Cold Chain Trends

      Cold Chain Trends

      There is a growing need for convenience through Direct-to-Patient and Direct-from-Patient services in clinical trials.
      Vince Paolizzi, Director of NanoCool Sales, Pelican BioThermal 11.17.20

    • Biologics, Proteins, Vaccines | Inspections | Supply Chain
      Inspecting the Unexpected

      Inspecting the Unexpected

      Preparing quality control processes for COVID-19 vaccine candidates.
      Dr. Andrea Sardella and Raffaele Pace, Stevanato Group 11.17.20


    • Scale-up/Technology Transfer
      Ensuring Quality During the Transfer and Scale Up of Rx Drugs

      Ensuring Quality During the Transfer and Scale Up of Rx Drugs

      Defining the key parameters and considerations for a successful technology transfer.
      Tom Chang, President, Bora Pharmaceutical Laboratory Co. Ltd. 11.17.20

    • Scale-up/Technology Transfer
      Modeling Process Safety Workflows in Pharmaceutical Manufacturing Scale-Up

      Modeling Process Safety Workflows in Pharmaceutical Manufacturing Scale-Up

      Identifying, assessing and mitigating threats at every stage of the development pipeline.
      Joe Willmot, Application Leader, H.E.L Group 11.17.20

    • Clinical Trials | Information Technology
      The Role of Electronic Monitoring in Maintaining Medication Adherence

      The Role of Electronic Monitoring in Maintaining Medication Adherence

      Digital solutions offer hope to get patients to take their medications properly.
      Bernard Vrijens, Scientific Lead, AARDEX Group 10.14.20


    • APIs
      Understanding the Importance of Crystallization Processes

      Understanding the Importance of Crystallization Processes

      Crystallization is a crucial aspect of a molecule’s development and can be used to avoid unnecessary cost, risk and development delays.
      Dr. Craig Callahan, Project Scientist, Cambrex Edinburgh 10.14.20

    • Capsules | Solid Dosage/Creams/Ointments
      Capsule Technology Trends

      Capsule Technology Trends

      A look at the capsule market with a particular focus on the factors driving increased demand in non-gelatin-based formulations.
      Julien Lamps, Product Manager, Lonza 10.14.20

    • Aseptic Processing | Fill/Finish
      A Holistic Cleanroom Concept: Higher Quality and Greater Flexibility

      A Holistic Cleanroom Concept: Higher Quality and Greater Flexibility

      Overcoming today’s aseptic fill-and-finish process challenges.
      Ute Schleyer, Project Manager, Site & Plant Development, Vetter 10.14.20

    Trending
    • Lonza To Exit Pharma Softgels And Liquid-Filled Hard Capsules
    • Roche Canada To Invest $500M To Create 500 Jobs In Ontario
    • Grifols Begins COVID-19 Plasma Treatment Trial
    • Fujifilm To Invest $2B In US Manufacturing Site
    • Virtual Clinical Trials: The Future Of Dermatology Studies
    Breaking News
    • Global Biosciences Co. Selects ValGenesis VLMS
    • Eisai Appoints Chief Clinical Officer of Oncology Biz
    • Nexelis Acquires GSK Vax Lab in Marburg
    • Bone Therapeutics, Rigenerand Ink Cell Therapy Deal
    • NovaQuest Private Equity Acquires CoreRx
    View Breaking News >
    CURRENT ISSUE

    November/December 2020

    • Modeling Process Safety Workflows in Pharmaceutical Manufacturing Scale-Up
    • Ensuring Quality During the Transfer and Scale Up of Rx Drugs
    • Inspecting the Unexpected
    • Cold Chain Trends
    • Catering for the Complex
    • Biopharma Contract Manufacturing: Robust Growth Ahead
    • DCAT President Talks COVID-19, Drug Manufacturing and Innovation
    • The Single-Use Mixing Landscape: Evaluating Your Options
    • Self-Medication: Flexibility for Patients and Drug Manufacturers
    • Decentralized Trials Fuel AI Revolution in Clinical Research
    • View More >

    Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
    You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

    • About Us
    • Privacy Policy
    • Terms And Conditions
    • Contact Us

    follow us

    Subscribe
    Nutraceuticals World

    Latest Breaking News From Nutraceuticals World

    Ingredient Manufacturers Discuss the E-Sports Market
    Euromonitor Names Top Ten Trends for 2021
    Study Highlights Differences Between EPA's and DHA's Effect on Sleep
    Coatings World

    Latest Breaking News From Coatings World

    IGL Coatings Launches Graphene Reinforced Dual System Ceramic Coating
    Miller Paint Declares Simple Serenity its 2021 Color of the Year
    TAUBMANS Paint by PPG Releases ‘Chromatic Joy’ Palettes
    Medical Product Outsourcing

    Latest Breaking News From Medical Product Outsourcing

    Eitan Medical Receives FDA Clearance for Sapphire Infusion System
    Researchers Successfully ‘Fine Tune’ New Thermoplastic Biomaterial
    RSIP Vision Announces Versatile Medical Image Segmentation Tool
    Contract Pharma

    Latest Breaking News From Contract Pharma

    Global Biosciences Co. Selects ValGenesis VLMS
    Eisai Appoints Chief Clinical Officer of Oncology Biz
    Nexelis Acquires GSK Vax Lab in Marburg
    Beauty Packaging

    Latest Breaking News From Beauty Packaging

    Top Beauty Brands in the World—And Most Loved Fragrances
    P&G Reports Q2 Results
    A Lacquering Technique Makes Very Good Girl by Carolina Herrera Shine
    Happi

    Latest Breaking News From Happi

    Flow Launches Collagen Waters
    Associations Congratulate Biden & Harris
    David Stanko Joins JPMS
    Ink World

    Latest Breaking News From Ink World

    Morancé Soudure France Adds Comexi F2 MC 10-color Flexo Press
    THIMM Group Installs 1st Koenig & Bauer CorruFLEX
    Cowan Graphics Adds Fujifilm Inca OnsetX3 HS
    Label & Narrow Web

    Latest Breaking News From Label & Narrow Web

    Domino grows installation and service teams
    ABG keeps pace with demand with recruitment drive
    Acucote expands FSC-certified portfolio
    Nonwovens Industry

    Latest Breaking News From Nonwovens Industry

    First Quality Launches Incognito by Prevail
    Essity Launches Reusable Underwear Product
    Honeywell Delivered 225 Million Masks in December
    Orthopedic Design & Technology

    Latest Breaking News From Orthopedic Design & Technology

    DJO Acquires Trilliant Surgical
    FDA Breakthrough Device Designation Granted to Spiderwort's Spinal Cord Technology
    Bioventus Appoints SVP of Operations
    Printed Electronics Now

    Latest Breaking News From Printed Electronics Now

    UDC Subsidiary Adesis' Website Wins 2020 MarCom Platinum Award
    Roadsimple Modernizes Warehouse Ops with Zebra Technologies
    Graphene Flagship Launches Redesigned Website

    Copyright © 2021 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

    AD BLOCKER DETECTED

    Our website is made possible by displaying online advertisements to our visitors.
    Please consider supporting us by disabling your ad blocker.


    FREE SUBSCRIPTION Already a subscriber? Login